Femasys Inc. (FEMY) Fair Value 2026

FEMY · Surgical & Medical Instruments & Apparatus ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.1 /10

32 fundamental signals · 11 models active

Value Trap Risk

LOW (36/100)

Quick Summary — As of 2026-07-15, Femasys Inc. (FEMY) trades at $3.57, approximately 151% above CirclFi’s Bayesian DCF fair value of $1.42. QOC: 5.1/10. Value Trap Risk: 36/100 (LOW). 11/13 models active.

Key Facts

Ticker
FEMY
Price
$3.57
Quality Score
5.1/10
Value Trap Risk
36/100
Models Active
11/13
Last Updated
Strength: CUCE Ensemble suggests +1.8% upside with 2% confidence
Risk: Majority of models suggest overvaluation

Is Femasys Inc. (FEMY) Undervalued or Overvalued in 2026?

According to CirclFi’s 11-model valuation engine, Femasys Inc. (FEMY) appears overvalued as of : the median of 11 independent fair value estimates is $1.44, 59.5% below the current price of $3.57. Estimates range from $0.01 to $12.75. FEMY scores 5.1/10 on fundamental quality and 36/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Femasys Inc. Stock in 2026? →

Valuation Matrix

11 Intrinsic Value Models vs. Current Price ($3.57)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $1.42 -60.2%
Earnings Power Value
Medium Conviction
 $1.44 -59.5%
CUCE Ensemble
Low Conviction
 $3.63 +1.8%
First Chicago
Medium Conviction
 $0.02 -99.4%

Unlock the Full Matrix

Access 7 additional models including EROIC Spread, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 11 Models →

Cancel anytime · No contracts · Instant access

What Is Femasys Inc. (FEMY) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Femasys Inc. at its current price of $3.57. The composite intrinsic value is estimated at $2.97 (-16.8% average return), with 7 models flagging overvaluation risk. Model dispersion is worth noting: EROIC targets $12.75 (+257.2%), versus ML-RIV at $0.01 (-99.8%). This +357.1% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About FEMY?

11 of 13 models are currently active for FEMY. Of these, 4 models suggest upside while 7 models suggest overvaluation. The Bayesian DCF estimates FEMY's intrinsic value at $1.42, implying -60.2% downside from the current price. See which stocks rank higher →

How Does FEMY Rank in Surgical & Medical Instruments & Apparatus?

Among 109 Surgical & Medical Instruments & Apparatus stocks, FEMY ranks #82 by Quality of Company score. CirclFi's QOC score of 5.1/10 evaluates 32 fundamental signals. A score of 5.1 reflects mixed fundamentals.

See all Most Undervalued Surgical & Medical Instruments & Apparatus Stocks →

Femasys Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is FEMY a Value Trap?

CirclFi's Value Trap algorithm assigns FEMY a score of 36/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

11 of 13 models are active for Femasys Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Femasys Inc.'s fundamental quality profile registers 5.1/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +357.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every FEMY valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across FEMY's 11 active models, average confidence is 21%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Femasys Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Surgical & Medical Instruments & Apparatus Stocks Should You Also Analyze?

8 related Surgical & Medical Instruments & Apparatus stocks with 13-model coverage

DXCMDexCom, Inc.QOC 10.0IRMDiRadimed CorporationQOC 10.0PODDInsulet CorporationQOC 10.0RMDResMed Inc.QOC 10.0WSTWest Pharmaceutical Services, IQOC 9.9HAEHaemonetics CorporationQOC 9.8LMATLeMaitre Vascular, Inc.QOC 9.8GMEDGlobus Medical, Inc.QOC 9.2

Read investment analysis: DXCM · IRMD · PODD · RMD · WST

See all Surgical & Medical Instruments & Apparatus stocks ranked →

Frequently Asked Questions About Femasys Inc.

What is Femasys Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Femasys Inc. (FEMY) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $1.42. The Quality of Company score is 5.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is FEMY overvalued or undervalued right now?

At $3.57, 4 of 11 active models suggest FEMY may be undervalued, while 7 indicate potential overvaluation. The median of all 11 fair value estimates is $1.44, 59.5% below the current price of $3.57 — a consensus view that FEMY is overvalued. The assessment depends on which methodology best fits Femasys Inc.'s business model in Surgical & Medical Instruments & Apparatus.

What does a Quality of Company score of 5.1 mean for FEMY?

Femasys Inc.'s QOC of 5.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on FEMY?

CirclFi analyzes FEMY with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 11 of 13 are active for this stock. Read the full methodology →

Is FEMY a value trap in 2026?

Femasys Inc.'s Value Trap score is 36/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 11-model valuation engine, Femasys Inc. (FEMY) has a median fair value of $1.44 — 59.5% below the current price of $3.57 — as of 2026-07-15.” Source: circlfi.com/stock/FEMY/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 11 mathematical frameworks give you clarity on FEMY.

Unlock All 11 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access